Poor functional antibody responses are present in nearly all patients with chronic lymphocytic leukaemia, irrespective of total IgG concentration, and are associated with increased risk of infection-Reference-Cited by-同舟云学术

Poor functional antibody responses are present in nearly all patients with chronic lymphocytic leukaemia, irrespective of total IgG concentration, and are associated with increased risk of infection

Published:2015-04-28 Issue:5 Volume:171 Page:887-890
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Parry Helen M.¹,Birtwistle Jane²,Whitelegg Alison²,Hudson Chris³,McSkeane Tina⁴,Hazlewood Peter⁴,Mudongo Nyasha⁵,Pratt Guy¹,Moss Paul¹,Drayson Mark T.²,Murray Jim⁶,Richter Alex G.¹

Affiliation:

1. Cancer Sciences; University of Birmingham; Birmingham UK

2. Department of Immunology; University of Birmingham; Birmingham UK

3. School of Medicine and Veterinary Science; University of Nottingham; Nottingham UK

4. Cancer Research UK Clinical Trials Unit; University of Birmingham; Birmingham UK

5. University of Birmingham Medical School; Birmingham UK

6. Department of Haematology; University Hospital Birmingham; Birmingham UK

Funder

Wellcome Trust Fellowship

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13455/fullpdf

Reference10 articles.

1. Serum immunoglobulins in chronic lymphocytic leukemia;Ben-Bassat;American Journal of the Medical Sciences,1979

2. The immunodeficiency of chronic lymphocytic leukaemia;Hamblin;British Medical Bulletin,2008

3. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine;Jackson;Vaccine,2007

4. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants;Jodar;Vaccine,2003

5. Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy;Lu;Vaccine,2014

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Approach in the Management of Secondary Immunodeficiency in Patients with Hematological Malignancies: Spanish Expert Consensus Recommendations;Journal of Clinical Medicine;2023-10-04

2. Clinical and laboratory characteristics of patients with symptomatic secondary immunodeficiency following the treatment of haematological malignancies;eJHaem;2023-04

3. Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia;Journal of Hematology & Oncology;2022-01-09

4. Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia;Frontiers in Immunology;2021-10-25

5. Guideline for the treatment of chronic lymphocytic leukaemia;British Journal of Haematology;2018-07-15